Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2750
Single User License Price INR 196158
Corporate User License Price USD 4500
Corporate User License Price INR 320985
Site License Price USD 3500
Site License Price INR 249655
Request a Quote

Report Title

Global Oncology Drugs Market 2018-2024

Quote Request for License Type
License Type Price  
Single User License USD 2750
Site License USD 3500
Enterprise Wide License USD 4500
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Global Oncology Drugs Market 2018-2024


Quote Request for License Type
License Type Price  
Single User License USD 2750
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Global Oncology Drugs Market 2018-2024

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Global Oncology Drugs Market 2018-2024



Executive Summary

Global Oncology Drugs Market-Drivers, Restraints, Opportunities, Trends, and Forecasts: 2018-2024

Overview: Oncology drugs or anti-cancer drugs or anti-neoplastic drugs are agents that can be used alone or in combination to control or destroy neoplastic cells. These agents can be either systemic or targeted. In systemic, the drug spreads throughout the body, whereas in targeted, the drug or substance identifies the specific location causing less harm to the growth of neighboring healthy cells. The oncology drugs market, by applications, is segmented into breast cancer, blood cancer, prostate cancer, gastrointestinal cancer, lung cancer, and others. The incidence of cancer is one of the leading causes of death globally due to unhealthy food habits, changing lifestyle, and increasing consumption of tobacco-related products. According to the estimation of the National Cancer Institute, in the US, around 1.6 million new cases of cancer were diagnosed and 595,690 people died due to cancer in 2016. Nearly 60% of new cancer cases are from Africa, Asia, Central and South American countries and almost 70% of cancer deaths are from these regions. The Indian Council for Medical Research estimated around 1.4 million new cancer cases in 2016, which is expected to rise to 1.7 million cases by 2020.

Increased prevalence of cancer, unhealthy lifestyle, and increasing geriatric population are the primary factors driving the market growth. However, the high cost of the drug & development process and side effects of the drug are the factors hampering the market growth. The development of pipeline oncology products and expiry of key patents are providing an opportunity for the manufacturers of cancer drugs.

Market Analysis: The global oncology drugs market is estimated to witness a CAGR of 7.0% during the forecast period 2018-2024. The market is analyzed based on three segments: therapeutic modality, applications, and regions.

Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (RoW). North America is set to be the leading region for the oncology drugs market growth followed by Europe, Asia Pacific, and Rest of the World.

Therapeutic Modality Analysis: The global oncology drugs market by therapeutic modality is segmented into chemotherapy, immunotherapy, targeted therapy, and others. Chemotherapy occupied the largest share in 2017, and immunotherapy is expected to grow at a high CAGR in the coming years due to high efficiency, increased preference of targeted immunotherapy from chemotherapy, and fewer side effects.

Applications Analysis: The global oncology drugs market by applications is segmented into breast cancer, blood cancer, prostate cancer, gastrointestinal cancer, lung cancer, and others. Blood cancer occupied the largest share in 2017, and lung cancer application is expected to be the fastest growing segment during the forecast period due to the high incidence of lung cancer and promising pipeline for NSCLC drugs.

Key Players: F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb, Novartis AG, Johnson & Johnson, Pfizer, Inc., Celgene Corporation, AstraZeneca PLC, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Merck & Co., AbbVie, Inc., Sanofi, and other predominate & niche players.

Competitive Analysis: The high adoption of personalized medicine and immuno-oncology have fueled a shift in cancer treatment from chemotherapy in the past decade. During 2011-2017, around 84 new drugs have been approved across 22 indications globally, of which immuno-oncology PD-1 and PD-L1 inhibitors have seen a speedy uptake based on their notable clinical profile and approval for various cancers. Additionally, there is a robust late-stage oncology pipeline with around 630 unique molecules in the development, i.e., more than 7% when compared to the previous year, including 278 biological therapies and 82 vaccines. The market is dominated by key vendors such as F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb, Novartis AG, Celgene Corporation, Pfizer Inc., and Johnson & Johnson; and products of these firms are available globally through their distributors and subsidiaries.

Benefits: The report provides complete details about the usage and adoption of oncology drugs in various applications and regions. With that, key stakeholders can know about the major trends, drivers, investments, vertical player's initiatives, government initiatives toward the product adoption in the upcoming years along with the details of commercial products available in the market. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in specific verticals to analyze before investing or expanding the business in this market.

Key Stakeholders:

Table of Contents

1 INDUSTRY OUTLOOK 9

1.1 Industry overview 9

1.2 Industry Trends 9

1.3 Total addressable market 10

1.4 Trends of cancer therapy market 11

2 Report Outline 11

2.1 Report Scope 11

2.2 Report Summary 12

2.3 Research Methodology 12

2.4 Report Assumptions 13

3 Market Snapshot 14

3.1 Market Definition-Infoholic Research 14

3.2 Segmented Addressable Market (SAM) 14

3.3 Trends of the oncology drugs market 15

3.4 Related Markets 16

3.4.1 Over the counter drugs (OTC) 16

3.4.2 Active pharmaceutical ingredients (APIs) 17

3.4.3 Diabetes Drugs 17

4 Market Outlook 18

4.1 Oncology Drugs Approved by FDA (2014-2018) 18

4.2 Market segmentation 22

4.3 PEST Analysis 23

4.4 Porter 5(Five) Forces 24

5 Market Characteristics 25

5.1 DRO-Global Oncology Drugs Market Dynamics 25

5.1.1 Drivers 25

5.1.1.1 Increasing incidence of cancer across the globe 25

5.1.1.2 Growing geriatric population 26

5.1.1.3 Expiration of patents 26

5.1.2 Opportunities 27

5.1.2.1 Growing focus on personalized medicine 27

5.1.2.2 Increasing healthcare spending 27

5.1.3 Restraints 28

5.1.3.1 High cost of the drug 28

5.1.3.2 Side effects of oncology drugs 28

6 Therapeutic modality: Market Size and Analysis 31

6.1 Overview 31

6.2 Chemotherapy 32

6.3 Targeted therapy 33

6.4 Immunotherapy 34

6.5 Others 35

7 Application: Market Size and Analysis 37

7.1 Overview 37

7.2 Blood cancer 37

7.3 Breast cancer 38

7.4 Gastro intestinal cancer 39

7.5 Lung cancer 39

7.6 Prostate cancer 40

7.7 Others 40

8 Regions: Market Size and Analysis 41

8.1 Overview 41

8.2 North America 42

8.2.1 Overview 42

8.2.2 US 43

8.2.3 Canada 44

8.3 Europe 44

8.3.1 Overview 44

8.3.2 UK 45

8.3.3 Germany 46

8.3.4 France 46

8.3.5 Italy 46

8.4 APAC 47

8.4.1 Overview 47

8.4.2 India 48

8.4.3 China 48

8.5 Rest of the World 49

9 Competitive Landscape 50

9.1 Overview 50

10 Vendor Profiles 53

10.1 F.Hoffmann-La Roche Ltd 53

10.1.1 Overview 53

10.1.2 Business Unit 56

10.1.3 Geographic Presence 57

10.1.4 58

10.1.5 Business Focus 58

10.1.6 SWOT Analysis 58

10.1.7 Business Strategy 59

10.2 Novartis AG 60

10.2.1 Overview 60

10.2.2 Business Unit 63

10.2.3 Geographic Presence 63

10.2.4 Business Focus 64

10.2.5 SWOT Analysis 64

10.2.6 Business Strategy 65

10.3 Bristol-Myers Squibb 66

10.3.1 Overview 66

10.3.2 Geographic Presence 70

10.3.3 Business Focus 71

10.3.4 SWOT Analysis 71

10.3.5 Business Strategy 72

10.4 Celgene Corporation 73

10.4.1 Overview 73

10.4.2 Geographic Presence 75

10.4.3 Business Focus 75

10.4.4 SWOT Analysis 75

10.4.5 Business Strategy 76

10.5 Johnson & Johnson 77

10.5.1 Overview 77

10.5.2 Business Units 80

10.5.3 Geographic Revenue 81

10.5.4 Business Focus 82

10.5.5 SWOT Analysis 83

10.5.6 Business Strategies 83

10.6 Pfizer Inc., 84

10.6.1 Overview 84

10.6.2 Geographic Presence 87

10.6.3 Business Focus 88

10.6.4 SWOT Analysis 89

10.6.5 Business Strategies 89

11 Companies to Watch For 90

11.1 Astra Zenca PLC 90

11.1.1 Overview 90

11.2 Eli Lilly and Company. 91

11.2.1 Overview 91

11.3 GlaxoSmithKline plc 92

11.3.1 Overview 92

11.4 Merck & Co. 94

11.4.1 Overview 94

11.5 Sanofi 95

11.5.1 Overview 95

11.6 Amgen Inc. 96

11.6.1 Overview 96

11.7 AbbVie, Inc. 98

11.7.1 Overview 98

12 Annexure 100

12.1 Abbreviations 100

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

Charts

CHART 1 RESEARCH METHODOLOGY OF GLOBAL ONCOLOGY DRUGS MARKET 12

CHART 2 GLOBAL ONCOLOGY DRUGS MARKET REVENUE, 2017-2024 (USD BILLION) 15

CHART 3 NUMBER OF ONCOLOGY DRUGS APPROVED FROM 2014-2017 22

CHART 4 SEGMENTATION OF GLOBAL ONCOLOGY DRUGS MARKET 22

CHART 5 PEST ANALYSIS OF GLOBAL ONCOLOGY DRUGS MARKET 23

CHART 6 PORTER 5 FORCES ON GLOBAL ONCOLOGY DRUGS MARKET 24

CHART 7 DRO-IMPACT ANALYSIS OF GLOBAL ONCOLOGY DRUGS MARKET 29

CHART 8 KEY STAKEHOLDERS 29

CHART 9 GLOBAL ONCOLOGY DRUGS MARKET BY THERAPEUTIC MODALITY SEGMENTATION, 2017 (%) 31

CHART 10 GLOBAL ONCOLOGY DRUGS MARKET BY THERAPEUTIC MODALITY SEGMENTATION, 2024 (%) 31

CHART 11 GLOBAL CHEMOTHERAPY MARKET FORECAST, 2017-2024 (USD BILLION) 33

CHART 12 GLOBAL TARGETED THERAPY MARKET FORECAST, 2017-2024 (USD BILLION) 34

CHART 13 GLOBAL IMMUNOTHERAPY MARKET FORECAST, 2017-2024 (USD BILLION) 35

CHART 14 GLOBAL OTHERS MARKET FORECAST, 2017-2024 (USD BILLION) 36

CHART 15 GLOBAL ONCOLOGY DRUGS MARKET BY APPLICATION SEGMENTATION, 2017 (%) 37

CHART 16 GLOBAL ONCOLOGY DRUGS MARKET BY GEOGRAPHICAL SEGMENTATION, 2017 (%) 41

CHART 17 ONCOLOGY DRUGS MARKET REVENUE IN NORTH AMERICA, 2017-2024 (USD BILLION) 43

CHART 18 ONCOLOGY DRUGS MARKET REVENUE IN EUROPE, 2017-2024 (USD BILLION) 45

CHART 19 ONCOLOGY DRUGS REVENUE IN ASIA-PACIFIC, 2017-2024 (USD BILLION) 47

CHART 20 ONCOLOGY DRUGS MARKET REVENUE IN REST OF THE WORLD, 2017-2024 (USD BILLION) 50

CHART 25 NOVARTIS AG: OVERVIEW SNAPSHOT 62

CHART 26 NOVARTIS AG: BUSINESS UNITS 63

CHART 27 NOVARTIS GA: GEOGRAPHICAL PRESENCE 63

CHART 28 NOVARTIS AG: SWOT ANALYSIS 64

CHART 29 BRISTOL-MYERS SQUIBB.: OVERVIEW SNAPSHOT 68

CHART 30 BRISTOL-MYERS SQUIBB.: BUSINESS SEGMENTS 69

CHART 31 BRISTOL-MYERS SQUIBB.: GEOGRAPHIC PRESENCE 70

CHART 32 BRISTOL-MYERS SQUIBB.: SWOT ANALYSIS 71

CHART 33 CELGENE CORPORATION: OVERVIEW SNAPSHOT 74

CHART 34 CELGENE CORPORATION: GEOGRAPHIC PRESENCE 75

CHART 35 CELGENE CORPORATION: SWOT ANALYSIS 75

CHART 36 JOHNSON & JOHNSON: OVERVIEW SNAPSHOT 80

CHART 37 JOHNSON & JOHNSON: BUSINESS UNITS 80

CHART 38 JOHNSON & JOHNSON: GEOGRAPHIC REVENUE 81

CHART 39 JOHNSON & JOHNSON: SWOT ANALYSIS 83

CHART 40 PFIZER INC.,: OVERVIEW SNAPSHOT 86

CHART 41 PFIZER INC.: BUSINESS UNITS REVENUE 87

CHART 42 PFIZER INC.: GEOGRAPHICAL PRESENCE 87

CHART 43 PFIZER INC.: SWOT ANALYSIS 89

Tables

TABLE 1 GLOBAL ONCOLOGY DRUGS MARKET REVENUE BY REGIONS, 2017-2024 (USD BILLION) 42

TABLE 1 GLOBAL ONCOLOGY DRUGS MARKET BY VENDOR RANKING, 2017 52

TABLE 2 OTHER PROMINENT VENDORS OF ONCOLOGY DRUGS MARKET 53

TABLE 3 F. HOFFMANN-LA ROCHE: OFFERINGS 54

TABLE 4 F. HOFFMANN-LA ROCHE: RECENT DEVELOPMENTS 54

TABLE 5 NOVARTIS AG: OFFERINGS 60

TABLE 6 NOVARTIS AG: RECENT DEVELOPMENTS 61

TABLE 7 BRISTOL-MYERS SQUIBB: OFFERINGS 66

TABLE 8 BRISTOL-MYERS SQUIBB: RECENT DEVELOPMENT 67

TABLE 9 CELGENE CORPORATION: OFFERINGS 73

TABLE 10 CELGENE CORPORATION: RECENT DEVELOPMENTS 73

TABLE 11 JOHNSON & JOHNSON: PRODUCT OFFERINGS 77

TABLE 12 JOHNSON & JOHNSON: RECENT DEVELOPMENTS 78

TABLE 13 PFIZER, INC.: PRODUCT OFFERINGS 84

TABLE 14 PFIZER INC.: RECENT DEVELOPMENTS 85

TABLE 15 ASTRA ZENECA PLC.: SNAPSHOT 90

TABLE 16 ASTRA ZENECA PLC: RECENT DEVELOPMENTS 90

TABLE 17 ELI LILLY AND COMPANY: SNAPSHOT 91

TABLE 18 ELI LILLY AND COMPANY: RECENT DEVELOPMENTS 91

TABLE 19 GLAXOSMITHKLINE PLC.: OVERVIEW 92

TABLE 20 GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS 93

TABLE 21 MERCK & CO: OVERVIEW 94

TABLE 22 MERCK & CO: RECENT DEVELOPMENTS 94

TABLE 23 SANOFI: SNAPSHOT 95

TABLE 24 SANOFI: RECENT DEVELOPMENTS 96

TABLE 25 AMGEN INC.: SNAPSHOT 97

TABLE 26 AMGEN INC: RECENT DEVELOPMENTS 97

TABLE 27 ABBVIE INC: SNAPSHOT 98

TABLE 28 ABBVIE INC: RECENT DEVELOPMENTS 99

F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb, Novartis AG, Johnson & Johnson, Pfizer, Inc., Celgene Corporation, AstraZeneca PLC, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Merck & Co., AbbVie, Inc., Sanofi, and other predominate & niche players


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person